Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
VLX Ventures is a venture capital firm based in Israel, dedicated to advancing drug development and computational biology. Founded with the mission to identify and nurture startups that leverage cutting-edge technologies in the biopharma sector, VLX Ventures plays a pivotal role in supporting the growth of innovative companies. The firm focuses on intensive research and development, business validation, and team recruitment to ensure the success of its portfolio companies. With a strong emphasis on addressing challenging diseases, VLX Ventures has established itself as a key player in the biopharma investment landscape.
Since its inception, VLX Ventures has raised multiple funds, although specific fund sizes and assets under management (AUM) are not publicly disclosed. The firm operates across various stages of investment, including pre-seed, seed, seed-plus, and Series A, allowing it to engage with startups at different points in their development. The leadership team comprises experienced professionals with extensive backgrounds in the biopharma industry, providing valuable insights and guidance to portfolio companies.
VLX Ventures primarily invests in biopharma therapeutic ventures that are focused on developing drugs for challenging diseases. The firm has a particular interest in digital pharma ventures that combine deep biology with computational biology, facilitating advancements in precision medicine and diagnostics. This dual focus allows VLX Ventures to support companies that are not only innovating in drug development but also enhancing the overall healthcare landscape through technology integration.
The firm is open to investing in startups at various stages, from early pre-clinical research to advanced Phase 3 clinical studies. This flexibility enables VLX Ventures to engage with a diverse range of companies, providing them with the necessary capital and resources to progress through critical development phases. The typical seed investment size is around $1 million, which allows for substantial support during the early stages of a startup's journey.
VLX Ventures is particularly interested in sectors such as multiomics, cancer therapies, autism and fertility treatments (IVF), immunotherapy, anti-infective drugs, targeted neutrophilic therapy, cell therapy for cancer, and ophthalmology. By focusing on these areas, VLX Ventures aims to back companies that are tackling some of the most pressing health challenges of our time, ultimately contributing to improved patient outcomes and healthcare solutions.
VLX Ventures boasts a diverse portfolio that includes companies engaged in various sectors of biopharma. Notable areas of investment encompass multiomics, cancer therapies, autism and fertility treatments (IVF), immunotherapy, anti-infective drugs, targeted neutrophilic therapy, cell therapy for cancer, and ophthalmology. This broad spectrum of investments reflects the firm's commitment to addressing a wide range of challenging diseases and health conditions.
While specific company names and outcomes are not disclosed, the portfolio's focus on innovative therapeutic solutions positions VLX Ventures as a significant contributor to advancements in the biopharma sector. The firm actively seeks to partner with startups that demonstrate potential for groundbreaking developments in drug therapies, thereby enhancing the overall efficacy and accessibility of healthcare solutions.
To pitch VLX Ventures, founders should email their proposals to admin@vlx.co.il. It is recommended to include a detailed overview of the startup, its technology, and how it aligns with VLX's focus on biopharma innovation.
VLX Ventures invests in various stages, including pre-seed, seed, seed-plus, and Series A. This allows them to support startups at different points in their development journey.
To pitch VLX Ventures, founders can reach out via email at admin@vlx.co.il. It is advisable to provide a clear overview of the startup, its technology, and how it aligns with VLX's investment focus.
VLX Ventures primarily focuses on the biopharma sector, particularly in areas such as multiomics, cancer therapies, autism and fertility treatments, immunotherapy, and more. They seek to invest in companies that are developing innovative solutions for challenging diseases.
The typical seed investment size from VLX Ventures is around $1 million. This investment allows startups to advance their research and development efforts significantly.
VLX Ventures is based in Israel and primarily invests in startups located in the biopharma sector, although they may consider opportunities in other regions that align with their investment thesis.
Founders interested in applying for investment from VLX Ventures should prepare a comprehensive pitch and send it via email to admin@vlx.co.il. Clear communication of the startup's vision and alignment with VLX's focus areas is essential.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.